News about Clinical Trials

CStone's CS2009 Secures U.S. FDA IND Clearance for Phase II Trial in Advanced Solid Tumours

CStone Pharmaceuticals has received U.S. FDA IND clearance to begin a Phase II trial of its trispecific antibody CS2009 for advanced solid tumours, advancing its global immunotherapy development programme.

Clinical Trials | 16/02/2026 | By News Bureau |  190

Innovent Doses First Patient in Phase III Trial of IBI354 for First-Line HER2-Positive Advanced Breast Cancer

HeriCare-Breast01 study evaluates next-generation HER2 ADC against standard THInnovent BiologicsP regimen, following promising phase I/II efficacy and safety data presented at ASCO 2025.

Clinical Trials | 16/02/2026 | By News Bureau |  181

SOFIE Biosciences doses first patient in Phase III FAPI-PRO trial for pancreatic cancer imaging

SOFIE Biosciences has dosed the first patient in its Phase III FAPI-PRO trial evaluating 18F-FAPI-74 PET/CT for detecting metastatic pancreatic ductal adenocarcinoma, with 18 sites planned across 24 months.

Clinical Trials | 13/02/2026 | By News Bureau |  335

Centivax Begins Phase-I Trial of Universal Flu Vaccine

Unlike conventional seasonal influenza vaccines, which must be reformulated annually to attempt to match predicted circulating strains, Centi-Flu 01 is designed to focus both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate, and are shared across strains and distance subtypes.

Clinical Trials | 13/02/2026 | By News Bureau |  132

Annovis Secures DSMB Nod to Advance Phase-III Buntanetap Trial in Alzheimer's

During the open session, Annovis presented an overview of the trial status, including enrollment progress, adverse events and study timelines. In the closed session, attended exclusively by DSMB voting members to ensure full objectivity and by an unblinded reporting statistician, unmasked safety data were reviewed.

Clinical Trials | 13/02/2026 | By News Bureau |  185

ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis

FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.

Clinical Trials | 12/02/2026 | By News Bureau |  137

VectorY Doses First Patient in Phase I/II PIONEER-ALS Trial of TDP-43 Targeting Therapy VTx-002

VectorY initiates clinical evaluation of VTx-002, a first-in-class vectorised antibody therapy targeting TDP-43 pathology in ALS, with first patient dosed at Mass General Brigham.

Clinical Trials | 11/02/2026 | By News Bureau |  213

Roche's Fenebrutinib Matches Ocrevus in Slowing Disability Progression in PPMS Phase III Trial

Phase III FENtrepid study shows oral BTK inhibitor fenebrutinib achieved non-inferiority to Ocrevus in primary progressive multiple sclerosis, reducing disability progression risk by 12 percent with consistent subgroup benefit.

Clinical Trials | 10/02/2026 | By News Bureau |  194

Late-breaking Data Highlight Positive Safety and Closure Rates for Abbott's New Stroke-prevention Device in non-Valvular AFib

Abbott has reported positive late-breaking data from the VERITAS Study showing its Amulet 360 Left Atrial Appendage Occluder met safety and effectiveness endpoints, supporting its potential to reduce stroke risk in patients with non-valvular atrial fibrillation.

Clinical Trials | 09/02/2026 | By News Bureau |  210

Delonix Bioworks Secures NMPA IND Clearance for MenB Vaccine Candidate DX-104

China grants IND approval for DX-104 after Australia CTN clearance, paving the way for Phase I trials of Delonix’s engineered Group B meningococcal vaccine.

Clinical Trials | 09/02/2026 | By News Bureau |  262